Abstract: A method for promoting hair growth is disclosed. The method comprises a step of administering Lactobacillus paracasei GMNL-653 to a subject who needs to increase hair volume at a dose of 1.25×108 to 5×108 cells/ml/day, and the Lactobacillus paracasei GMNL-653 was deposited at the China Center for Type Culture Collection located at Wuhan University, Wuhan 430072 P.R. China on Apr. 25, 2016 under an accession number CCTCC NO. M 2016226.

Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: A probiotic composition of improving memory and learning ability is disclosed. The probiotic composition comprises Lactobacillus acidophilus GMNL-185 and Lactobacillus rhamnosus GMNL-680, wherein the Lactobacillus acidophilus GMNL-185 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017764, and the Lactobacillus rhamnosus GMNL-680 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017766, wherein a ratio of a number of bacteria of the Lactobacillus acidophilus GMNL-185 to a number of bacteria of the Lactobacillus rhamnosus GMNL-680 is 1:1.

Abstract: A strain of Lactobacillus paracasei for promoting hair growth, a hair product having same, and a use thereof are disclosed. The strain of Lactobacillus paracasei is Lactobacillus paracasei GMNL-653, which was deposited at the China Center for Type Culture Collection in Wuhan, China on Apr. 25, 2016 under an accession number CCTCC NO. M 2016226.

Abstract: A composition having Lactobacillus Plantarum strain GMNL-662 for promoting bone regrowth is provided. The Lactobacillus Plantarum strain GMNL-662 has an ability to promote the expression of osteogenic genes, inhibit the expression of osteoclast related genes, and promote the expression of osteogenesis-related cytokine TGF-?, so that the bone loss is improved.

Abstract: A method and a composition having the Lactobacillus paracasei strain GMNL-653 for treating psoriasis is provided. The Lactobacillus paracasei strain GMNL-653 has anti-inflammation properties, and inhibits the secretion of cytokine IL-6 and IL-17, so that the psoriasis symptoms caused by over-inflammation are improved/relieved.

Abstract: A method for inhibiting bacterial adhesion of oral pathogens, comprising administering a heat-inactivated Lactobacillus strain to a subject in need to inhibit bacterial adhesion of oral pathogens is disclosed. The Lactobacillus strain is selected from Lactobacillus paracasei GMNL-143, Lactobacillus helveticus GMNL-164 or Lactobacillus rhamnosus GMNL-464. A composition for inhibiting bacterial adhesion of oral pathogens is also disclosed.

Abstract: A use of a Lactobacillus paracasei strain to prepare a composition for resisting bone loss is provided. The Lactobacillus paracasei strain GMNL-653 is capable of promoting the expression of TGF-? and IL-10, while inhibiting the expression of osteoclast related genes and reducing the content of IL-17A in serum, so that the bone loss is slowed down.

Abstract: A composition of Lactobacillus fermentum GMNL-296 and a use of Lactobacillus fermentum GMNL-296 for producing a composition to improve the infection symptoms of Clostridium difficile are provided. The Lactobacillus fermentum GMNL-296 is to promote the expression of anti-inflammatory cytokine IL-10 and Treg cell related transcription factors, so that the infection symptoms of weight loss and intestinal abnormalities are improved.

Abstract: A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.

Abstract: Present invention features a method for controlling body weight, comprising Lactobacillus reuteri GMNL-263 with the deposition numbers of BCRC 910452 and CCTCC M 209263. Moreover, the invention also relates to a novel use of the composition or the isolated Lactobacillus strain for controlling body weight, whose mechanism is inhibiting biosynthesis of lipids and reducing formation of lipid droplets so as to control body weight.

Abstract: Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

Abstract: Present invention features a novel use of Lactobacillus for treating type 2 diabetes, wherein the Lactobacillus is Lactobacillus reuteri GMNL-89 with the deposition numbers of BCRC 910340 and CCTCC M 207154 and comprises of live, dead bacteria or supernatant of the bacterial culture(s) and a pharmaceutically acceptable vehicle. The invention also discloses the efficacies of the indicated Lactobacillus strain including anti-oxidative enzyme activity, anti-inflammation, reduction of blood glucose level, reduction of triglycerides, reduction of total cholesterol, reduction of LDL, increase of HDL and improve insulin utilization.

Abstract: Present invention features a method for controlling body weight, comprising Lactobacillus reuteri GMNL-263 with the deposition numbers of BCRC 910452 and CCTCC M 209263. Moreover, the invention also relates to a novel use of the composition or the isolated Lactobacillus strain for controlling body weight, whose mechanism is inhibiting biosynthesis of lipids and reducing formation of lipid droplets so as to control body weight.

Abstract: The present invention relates to a composition used for treating picornavirus infection comprising at least one of the following bacterial strains: Lactobacillus paracasei GMNL-33 with the deposition numbers of CCTCC M 206133, Lactobacillus reuteri GMNL-89 with the deposition numbers of CCTCC M 207154 and Lactobacillus casei GMNL-277 with the deposition numbers of CCTCC M 2013197, and a pharmaceutically acceptable vehicle. The Lactobacillus casei GMNL-277 of the invention is a novel Lactobacillus isolated strain. In addition, the present invention also features the novel use of the composition of the Lactobacillus strains for treating picornavirus infection, and the mechanism of which is inhibition of virus infection by binding of the probiotic bacteria to viruses.

Abstract: The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of Lactobacillus strain which is at least one selected from the group consisting of: Lactobacillus reuteri GMNL-89 strain, Lactobacillus gasseri GMNL-205 strain, Lactobacillus reuteri GMNL-263 strain and a pharmaceutical acceptable vehicle. The Lactobacillus gasseri GMNL-205 strain and Lactobacillus reuteri GMNL-263 strain are novel isolated Lactobacillus strains. In addition, the invention also relates to a novel use of the composition or the Lactobacillus strains for improving the syndrome of diabetes and complication thereof.

Abstract: The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of Lactobacillus strain which is at least one selected from the group consisting of: Lactobacillus reuteri GMNL-89 strain, Lactobacillus gasseri GMNL-205 strain, Lactobacillus reuteri GMNL-263 strain and a pharmaceutical acceptable vehicle. The Lactobacillus gasseri GMNL-205 strain and Lactobacillus reuteri GMNL-263 strain are novel isolated Lactobacillus strains. In addition, the invention also relates to a novel use of the composition or the Lactobacillus strains for improving the syndrome of diabetes and complication thereof.

Abstract: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject suffering from allergy Der p 5 is also provided.

Abstract: A Lactobacillus paracasei-containing product used for inhibiting dental diseases caused by bacteria is provided, which comprises a plurality of Lactobacillus paracasei for inhibiting the growth of bacteria of dental diseases. Particularly, foods, oral hygiene products or oral treatment medicine containing the Lactobacillus paracasei when being administered or applied to a user can inhibit or reduce the number of pathogens of dental caries and periodontal diseases in oral cavity of the user, thereby achieving the efficacy of preventing dental diseases, such as dental caries and periodontal diseases.

Abstract: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject suffering from allergy Der p 5 is also provided.